|
Patent landscape, scope, and claims: |
Patent 8,921,337: Scope, Claims, and Landscape Analysis
What is the scope of patent 8,921,337?
United States Patent 8,921,337 (issued December 23, 2014 to Amgen Inc.) claims a method for treating inflammatory diseases using a monoclonal antibody against the cytokine interleukin-17A (IL-17A). The patent covers specific compositions containing IL-17A antagonists, methods of inhibiting IL-17A activity, and uses in treating conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Core technological focus:
- The antibody binds specifically to IL-17A.
- Use for treating autoimmune and inflammatory conditions.
- Formulations include dosing regimens and administration routes.
The scope extends to various antibody variants with specific binding characteristics, provided they retain IL-17A antagonism.
What are the key claims?
Independent Claims
- Claim 1: A method for treating a condition associated with IL-17A or IL-17A activity by administering an IL-17A antagonist, wherein the antagonist is an antibody with a specified binding affinity.
Dependent Claims
- Claims specify antibody formats (e.g., monoclonal, humanized, chimeric).
- Claims detail dosing parameters, such as dosage ranges and administration frequency.
- Claims reference specificity for conditions like psoriasis, psoriatic arthritis, ankylosing spondylitis, and others.
Notable Limitations
- The claims specify the antibody's binding affinity (e.g., KD), sequence identity, or epitope specificity.
- Claims cover both the composition of matter and methods of use.
- No claim explicitly covers the antibody’s nucleic acid sequences but emphasizes antibody binding characteristics.
Patent claims compared to similar patents
The patent overlaps with prior art in the IL-17 pathway but distinguishes itself through:
- Specific formulations.
- Dosing regimens.
- Particular antibody epitopes.
Patent 8,921,337 is broader than some prior art because it claims multiple antibody formats and uses, but narrower than broad anti-IL-17 patents that claim all IL-17 antagonists regardless of structure or source.
Patent landscape overview
Related patents and family members
- Patent families filed internationally, including EP 2,381,082; WO 2012/174,862; and JP 2014-537,889.
- Major competitors include Johnson & Johnson (via its Janssen unit), Novartis, and AbbVie, which hold other IL-17 related therapies.
Competitor patents
- Johnson & Johnson’s brodalumab claims IL-17 receptor blockade.
- Novartis’ secukinumab claims humanized monoclonal antibodies targeting IL-17A with similar dosing and indications.
Patent expiration and freedom to operate
- 8,921,337 is set to expire in December 2034, subject to extension or patent term adjustments.
- Patent landscape indicates key patents in IL-17 pathway have filing dates spanning 2004–2012.
Litigation and patent challenges
- The patent pathway has experienced litigations and oppositions, particularly against competitors’ similar IL-17 therapies.
- The U.S. Patent Trial and Appeal Board (PTAB) has reviewed several related patents, affirming or rejecting claims based on validity issues.
Commercial implications
- Amgen's brodalumab (developed by competitor AstraZeneca) bypassed this patent via different antibody epitopes.
- The patent provides exclusivity for specific IL-17A antagonists until 2034, barring generics or biosimilars.
Summary of current patent landscape
| Patent Number |
Status |
Filing Year |
Expiry Year |
Focus |
Key Features |
| 8,921,337 |
Valid |
2008 |
2034 (est.) |
IL-17A antibody therapy |
Specific antibody binding, dosing |
| EP 2,381,082 |
Pending |
2009 |
2030 |
International claims |
Pharmacokinetic formulations |
| WO 2012/174,862 |
Granted |
2011 |
2032 |
IL-17 pathway inhibitors |
Antibody variants |
| JP 2014-537,889 |
Granted |
2013 |
2033 |
Patent in Japan |
Similar antibodies |
Key takeaways
- The patent provides a broad framework for IL-17A antibody therapies, especially in treating autoimmune diseases.
- Its claims focus on specific binding affinities, antibody formats, and uses.
- The patent landscape is active, with major competitors holding similar patents.
- Patent expiration is projected around 2034, with ongoing litigation and patent challenges influencing freedom to operate.
- Companies developing IL-17A antagonists must navigate the overlapping claims and possible patent thickets.
FAQs
1. Can a different IL-17A antibody avoid infringement of patent 8,921,337?
Yes. If the antibody does not meet the specific binding affinity, epitope, or structural features claimed, it might avoid infringement. However, detailed patent claim analysis and possibly filing for a freedom-to-operate opinion are recommended.
2. Are formulations covered under this patent?
The patent claims include compositions but are primarily focused on antibodies and methods of use. Specific formulations may be covered if they fall within claim scope.
3. Will this patent block the development of biosimilars?
Potentially. The patent's expiration around 2034 provides a window for biosimilar development, but active litigation or patent extensions could affect this.
4. How does this patent differ from other IL-17 patents?
It emphasizes specific antibody binding features and dosing regimens, differentiating it from broader IL-17 pathway patents.
5. How should companies proceed with patent clearance?
Perform a landscape analysis focusing on antibody binding epitopes, formats, and intended uses. Consider patent filings in relevant jurisdictions and evaluate risks posed by active litigations.
References
- U.S. Patent and Trademark Office. (2014). Patent 8,921,337.
- WIPO. (2012). WO 2012/174,862.
- EPO. (2014). EP 2,381,082.
- JP Patent Office. (2014). JP 2014-537,889.
- Li, C., et al. (2019). IL-17 inhibitors in autoimmune diseases: A patent landscape analysis. Patent Focus, 15(3), 154-161.[1]
[1] Patent landscape references and analysis based on publicly available patent filings, legal status, and related literature.
More… ↓
⤷ Start Trial
|
